文献速递肾小球疾病

丝氨酸蛋白酶HTRA1是80岁及以上膜性肾病的常见自身抗原

Serine protease HTRA1 is a common autoantigen in membranous nephropathy in patients of 80 years and older.
PubMed 文献 · Kidney Int · 2026-03-27

该研究在三个膜性肾病队列中评估HTRA1自身抗原的分布,包括157例全年龄PLA2R/THSD7A/NELL1/EXT1阴性患者、54例80岁及以上PLA2R阴性患者和45例PLA2R阴性恶性肿瘤相关患者。结果显示HTRA1阳性率在80岁及以上患者中达22.2%,显著富集于该年龄段,提示HTRA1检测应纳入高龄抗原阴性膜性肾病的诊断评估。

要点

  • 80岁及以上PLA2R阴性膜性肾病患者中HTRA1阳性率约22.2%。
  • HTRA1阳性在80岁及以上患者中显著富集,相对风险11.6。
  • 建议对80岁及以上抗原阴性膜性肾病患者检测HTRA1。

核心结论

  • HTRA1是80岁及以上PLA2R阴性膜性肾病中的常见自身抗原,约五分之一病例阳性。
  • 研究结果支持将HTRA1检测纳入80岁及以上抗原阴性膜性肾病的诊断评估。
  • 提示存在与年龄相关的膜性肾病亚型。

研究设计与样本

  • 研究纳入三个膜性肾病患者队列,经机构批准。
  • 队列1:157例连续全年龄PLA2R/THSD7A/NELL1/EXT1阴性膜性肾病患者,经质谱分型。
  • 队列2:54例80岁及以上PLA2R阴性膜性肾病患者,经石蜡免疫荧光评估。
  • 队列3:45例PLA2R阴性恶性肿瘤相关膜性肾病患者。
  • HTRA1阳性通过石蜡免疫荧光和/或质谱确定,比例比较采用Fisher精确检验。

主要发现

  • HTRA1阳性率在PLA2R/THSD7A/NELL1/EXT阴性膜性肾病患者中为1.9%。
  • HTRA1阳性率在80岁及以上患者中为22.2%。
  • HTRA1阳性率在PLA2R阴性恶性肿瘤相关膜性肾病患者中为6.7%。
  • 与全年龄抗原阴性队列相比,HTRA1阳性在80岁患者中显著富集,相对风险11.6(95%CI 3.4-39.7)。
  • 18例HTRA1阳性病例平均年龄81.5岁,66.7%为男性,83.3%有肾病范围蛋白尿。

临床怎么用

  • 对80岁及以上抗原阴性膜性肾病患者,应考虑进行HTRA1检测以明确诊断。
  • HTRA1阳性患者多表现为肾病范围蛋白尿,需结合临床评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Membranous nephropathy (MN) in very elderly patients frequently remains antigen-negative after routine testing, limiting diagnostic precision. Recently, serine protease high temperature requirement protein A1 (HTRA1) has been identified as a novel MN autoantigen. Here, we focused on patients 80 years and older with MN and sought to systematically evaluate this association. METHODS: Three cohorts of patients with MN were examined under institutional approval, including 157 consecutive all-age series of PLA2R/THSD7A/NELL1/EXT1-negative patients with MN typed by mass spectrometry; 54 PLA2R-negative MN in patients aged 80 years and older assessed by paraffin immunofluorescence; and 45 PLA2R-negative malignancy-associated patients with MN. HTRA1 positivity was determined by paraffin immunofluorescence and/or mass spectrometry. Clinical and histopathologic features were reviewed where available. Proportions were compared using Fisher's exact test. RESULTS: HTRA1 positivity was identified in 1.9% of patients with PLA2R/THSD7A/NELL1/EXT-negative MN, 22.2% of patients 80 years and older, and 6.7% of patients with PLA2R-negative malignancy-associated MN. Compared with the all-age antigen-negative cohort, HTRA1 positivity was significantly enriched in patients aged 80 years (relative risk 11.6; 95% confidence interval 3.4- 39.7). Across all 18 HTRA1-positive cases, mean age was 81.5, 66.7% were male, and 83.3% had nephrotic-range proteinuria. CONCLUSIONS: HTRA1 is a common autoantigen in PLA2R-negative MN among very elderly patients, occurring in approximately one in five cases aged 80 years or more. These findings support inclusion of HTRA1 testing in diagnostic evaluation of antigen-negative MN in patients 80 years and older and suggest the existence of an age-linked MN subtype.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Al-Rabadi LF, Storey AJ, Abuelsamen T, et al. Serine protease HTRA1 is a common autoantigen in membranous nephropathy in patients of 80 years and older. Kidney Int. 2026. PMID: 41905594. doi:10.1016/j.kint.2026.02.036

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。